IRIX
IRIDEX CORP
NASDAQ · Healthcare · Medical - Devices · US
$0.77
−5.48%Year over year
Reported trailing growth
- Revenue
- +3.7%
- EBITDA
- +52.7%
- EBIT
- +21.0%
- EPS
- +38.2%
- Free cash flow
- +70.0%
- Operating cash flow
- +70.5%
Forward estimates
Based on analyst estimates
- Revenue
- -69.9%
- EBITDA
- +145.2%
- EPS
- +109.8%
Three-year CAGR
- Revenue
- -2.6%
- EBITDA
- +61.8%
- EBIT
- +69.0%
- Net income
- +50.2%
- EPS
- +51.9%
- Free cash flow
- +69.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026